Stay updated on Gantenerumab Long-term Safety in AD Clinical Trial

Sign up to get notified when there's something new on the Gantenerumab Long-term Safety in AD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Gantenerumab Long-term Safety in AD Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record now indicates termination of the study of gantenerumab for Alzheimer's disease following a pre-planned analysis. This update changes the study status and completion information shown on the page.
    Difference
    0.3%
    Check dated 2025-11-03T13:49:49.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    41 days ago
    Change Detected
    Summary
    Significant update: new operating-status notice and version bump to v3.2.0; previous v3.1.0 tag removed. Core content impacted by the new status information.
    Difference
    3%
    Check dated 2025-10-06T04:21:03.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no other substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-28T23:42:35.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Patch release: Revision updated from v3.0.1 to v3.0.2; Back to Top link removed. No other substantive changes detected.
    Difference
    0.2%
    Check dated 2025-09-14T18:44:12.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-07T13:05:16.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of new facility names and locations, particularly in South Korea, Italy, Poland, and Turkey, while also removing some previously listed locations and related topics. Notably, the MedlinePlus related topic on Alzheimer's Disease has been removed, but new topics related to Alzheimer's caregivers have been added.
    Difference
    12%
    Check dated 2025-08-31T04:28:02.000Z thumbnail image

Stay in the know with updates to Gantenerumab Long-term Safety in AD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Gantenerumab Long-term Safety in AD Clinical Trial page.